

Awards and Recognition

2009

- The Chester County Chamber of Business & Industry recognized Frank Baldino, Jr., PhD for his contributions and service to the Chester County and Greater Philadelphia communities, and for his leadership in the pharmaceutical industry and to the company he founded 22 years ago. He was named 2009 CEO of the Year by the organization.
- In the 2009 *Pharmaceutical Executive* annual industry performance audit of publicly-traded pharmaceutical, biotechnology and generics companies, Cephalon ranked 6 of 27 based on an analysis of key 2007-2008 performance metrics, including change in revenue and enterprise value, enterprise value to sales, and profit to assets.
- For the second consecutive year, Cephalon was named one of America's best adoption-friendly workplaces by the Dave Thomas Foundation for Adoption. The list, determined by an analysis of adoption benefits available to employees, ranked Cephalon #2 among pharmaceutical companies and #36 of the top 100 companies.
- Cephalon was named to the 2009 *Fortune* list of America's 1000 largest companies for the third consecutive year, rising in rank from 952 to 903 in the complete list of American's largest companies. In the list of the largest pharmaceutical companies, Cephalon ranked 20.
- For the second time, Cephalon was named to the *Forbes* listing of the Best Big Companies in America, based on factors that included sales and earnings growth, debt to total capital ratio, earnings outlook and stock market returns. Cephalon was one of just 14 companies in the Drugs and Biotechnology sector included in the 2008 listing.

2008

- The American Society for Clinical Oncology (ASCO) lists Cephalon oncology treatment TREANDA third of 12 major advances in cancer prevention and treatment in 2008. Only studies that significantly altered the way a cancer is understood, or had an important impact on patient care, were included in the list.
- Cephalon is ranked 17th in *Automotive Fleet* magazine's Top 50 Hybrid Fleet list of commercial fleets, recognizing a corporate initiative designed to increase fuel efficiency, and reduce the carbon footprint and greenhouse gas emissions.
- Standard & Poor's adds Cephalon to the world-renowned S&P 500 Index. The Index represents the top 500 companies in leading industries of the U.S. economy. The S&P 500 is widely regarded as the best single gauge of the U.S. equities market.

- The Utah Technology Council 2008 Hall Of Fame inducted Dr. Theodore H. Stanley, who, in 1985 commercialized his 1983 product invention, ACTIQ[®] (oral transmucosal fentanyl citrate) C-II; ACTIQ became the first pain product marketed by Cephalon.
- Cephalon is included in the new NASDAQ OMX Biotechnology Index (NASDAQ:QGBI), a modified market-capitalization weighted index designed to track the performance of the largest and most liquid companies engaged in the biotechnology sector.
- Cephalon receives the AmerisourceBergen Manufacturer of the Year Award, Branded Pharmaceutical Sales Under \$300 Million, for the second consecutive year.
- Cephalon is named to the 2008 Dave Thomas Foundation for Adoption list of America's Top 100 employers with the best adoption benefits, ranking 3rd among pharmaceutical companies, and 26th out of the top 100 employers with the best adoption benefits.
- Eric Floyd, Cephalon Vice President of Worldwide Regulatory Affairs, is named by Pharmaceutical Executive as one of their "45 under 45" Emerging Leaders.
- Robert P. Roche, Jr., Cephalon Executive Vice President, Worldwide Pharmaceutical Operations, receives the Man of the Year Award from the Greater Philadelphia Chapter of the Leukemia & Lymphoma Society for spearheading the effort to raise funds for blood cancer research, education, and patient services.
- Cephalon Europe President Alain Aragues named a Chevalier of the Légion d'Honneur by the government of France in recognition of his contributions to the country, particularly his tireless efforts to improve healthcare standards for people suffering with HIV and his impressive record in creating jobs in the pharmaceutical industry. Since joining Cephalon in 2002, Alain has led the company's expansion throughout Europe.

2007

- Deloitte & Touche USA LLP named Cephalon to the 2007 Greater Philadelphia Technology Fast 50, which recognizes the 50 fastest growing technology, media, telecommunication and life sciences companies in the Greater Philadelphia area based on percentage revenue growth over five years.
- Cephalon was awarded the 2007 British American Business Council Explorer Award, given annually to a company in the greater Philadelphia region that has made a significant business investment in the United Kingdom.
- Cephalon CEO Frank Baldino, Jr., Ph.D. was named by PharmaVOICE as one of the "100 Most Inspiring People" and included in a list of entrepreneurs who are redefining the life-sciences industry through innovative approaches to improving technologies, processes, services and ultimately patient care.
- Cephalon was added to the NASDAQ-100 Index, which includes 100 of the largest non-financial domestic and international securities listed on the NASDAQ Stock Market based on market capitalization.
- Cephalon has joined the list of companies included in the FORTUNE 1000 annual ranking of America's largest corporations. Cephalon is one of only 19 companies in the pharmaceutical sector to make FORTUNE Magazine's list in 2007.

- The World Economic Forum inducted Cephalon into its “Community of Global Growth Companies” — a group of companies with revenues of \$100 million to \$2 billion, annual growth of more than 15%, a focus on global expansion strategies, and demonstrated leadership in a particular industry.
- R&D Directions magazine identified Cephalon compounds CEP-701 (lestaurtinib) for the treatment of acute myeloid leukemia, and TREANDA® (bendamustine HCl) for the treatment of nonHodgkin’s lymphoma, as two of the 100 Great Investigational Drugs of 2007.
- Industry Week ranked Cephalon as one of the 500 largest U.S. manufacturers in its annual reporting of the largest publicly held U.S. manufacturing companies based on revenue.
- Cephalon moved up from #458 in the 2006 ranking to #381 in 2007.

2006

- Frank Baldino, Jr., Ph.D., honored by the World Trade Center of Greater Philadelphia for his contributions to regional economic development.
- Dr. Baldino received the first Hubert J.P. Schoemaker Leadership Award, which recognizes a leader in the biosciences community who best exemplifies the spirit of innovation in the Commonwealth of Pennsylvania.
- Cephalon named winner of the 2006 Supplier of the Year Award in the midsize brand pharmaceutical category by McKesson Corporation.
- Cephalon ranked among the top 40 companies in The Scientist magazine’s “Best Places to Work in Industry” survey.

2005

- Cephalon co-sponsored BIO 2005, which attracted 18,000 people from 50 countries to the Greater Philadelphia Region. Cephalon advertising at AMTRAK’s 30th Street Station in Philadelphia was seen by the 18,000 attendees and general public.
- Named for the third consecutive year to the Deloitte & Touche Technology Fast 500, which recognizes the fastest-growing technology companies in the U.S. and Canada.
- Received the HD Smith Wholesale Drug Company Vendor of the Year award and the Cardinal Health Supplier Quality Award for superior quality of service.
- The Boy Scouts of America Cradle of Liberty Council honored Frank Baldino, Jr. with the technology “Good Scout” award.
- Ranked the sixth most admired biotechnology company by MedAdNews, a monthly magazine that covers marketing in the pharmaceutical business.

2004

- Named among worldwide biotechnology companies ranked by percentage of total revenue devoted to R&D in Leaders of Life Science magazine.
- Frank Baldino, Jr. honored with the Chester County Economic Development Council's Hall of Fame Award for outstanding achievements.
- Named to the 2004 edition of The Forbes 2000, a comprehensive list of the world's biggest and most powerful companies.
- PROVIGIL® (modafinil) Tablets [C-IV] listed by Drug Topics as number 113 among top 200 branded drugs in 2003, measured by retail dollars spent on prescriptions.
- Harvard Medical School Endowed Chair Named after Frank Baldino, Jr., Ph.D.
- Ranked by MedAdNews in "Top 10 Biotechnology Companies" list based on total revenues.
- Included in the Fortune 40—A Model Portfolio with the Best Investment Ideas for the Year Ahead.
- Named for the second consecutive year to the Deloitte & Touche Technology Fast 50 and the Fast 500 lists based on percentage of revenue growth over five years.

2003

- Named to the Forbes 500 list, a report card on how the biggest and most profitable companies perform.
- Listed on the Forbes list of Fastest Growing Technology Companies.
- Ranked among the top 10 "Most Admired Biotechnology Companies" by MedAdNews.
- Inducted into the Biotech Hall of Fame in the Best of Biotech 2003 Awards.
- Named "Entrepreneurial Company of the Year" by the Great Valley Chamber of Commerce.
- Named to the Deloitte & Touche Technology Fast 50 and the Fast 500 lists based on percentage of revenue growth over five years.
- Ranked by The Scientist magazine as one of the "Top 10 Best Places to Work."
- Selected to join the NASDAQ 100.
- Received the Deloitte & Touche Technology Fast 50 award as one of the fifty fastest-growing companies in America.
- Received the National Sleep Foundation Corporate Award for work in sleep medicine.
- Recognized by Invest in France and the French-American Chamber of Commerce. Honored by the Eastern Technology Council as Life Science Company of the Year.